


# Stabilis



## Ceftazidime Avibactam



Noms commerciaux

|           |  |
|-----------|--|
| Avycaz    | Etats Unis d'Amérique  |
| Torgena   | Brésil   |
| Zavicefta | Allemagne, Argentine, Australie, Belgique, Chili, Espagne, Etats Unis d'Amérique, Finlande, France, Grande Bretagne, Hongrie, Irlande, Italie, Luxembourg, Mexique, Norvège, Pérou, Roumanie, Slovénie, Suède, Suisse, Tunisie |


























### Stabilité des solutions

|  |    | 125/31,25 mg/ml    | 20-25°C |  | 24 |  |  | 4634 |
|--|----|--------------------|---------|--|----|--|--|------|
|  |    | 25/6,25 mg/ml      | 37°C    |  | 12 |  |  | 4634 |
|  |    | 8/2 >> 40/10 mg/ml | 2-8°C   |  | 24 |  |  | 2902 |
|  |    | 8/2 >> 40/10 mg/ml | 25°C    |  | 12 |  |  | 2902 |
|  | RL | 8/2 >> 40/10 mg/ml | 2-8°C   |  | 24 |  |  | 2902 |
|  | RL | 8/2 >> 40/10 mg/ml | 25°C    |  | 12 |  |  | 2902 |



### Compatibilités

|  | Ceftazidime Avibactam<br>Amikacin sulfate                                   | 3549 |
|--|---|------|
|  | Ceftazidime Avibactam : 8,25 & 50 mg/ml<br>Aztreonam : 10 & 20 mg/ml        |      |
|  | Ceftazidime Avibactam : 40 mg/ml<br>Cefiderocol sulfate tosylate : 20 mg/mL |      |
|  | Ceftazidime Avibactam : 40/10 mg/ml<br>Eravacycline : 0,6 mg/ml             |      |
|  | Ceftazidime Avibactam<br>Erythromycin lactobionate                          | 3674 |

|   |   |  |  |      |
|---|---|--|--|------|
|   |   | Ceftazidime Avibactam : 40/10 mg/ml<br>Fosfomycin : 30 mg/ml                 |   | 4055 |
|  |  | Ceftazidime Avibactam<br>Gentamicin sulfate                                  |  | 3520 |
|  |  | Ceftazidime Avibactam<br>Gentamicin sulfate                                  |  | 3643 |
|   |  | Ceftazidime Avibactam : 40/10 mg/ml<br>Plazomicin sulfate : 24 mg/ml         |  | 4145 |
|   |  | Ceftazidime Avibactam : 40/10 mg/ml<br>Sulbactam/durlobactam : 15/15 mg/ml   |  | 4801 |
|  |  | Ceftazidime Avibactam : 8 mg/ml<br>Vancomycin hydrochloride : 5 mg/ml        |  | 3984 |
|  |  | Ceftazidime Avibactam : 8 & 20 mg/ml<br>Vancomycin hydrochloride : 10 mg/ml  |  | 3984 |
|  |  | Ceftazidime Avibactam : 8 >> 40 mg/ml<br>Vancomycin hydrochloride : 15 mg/ml |  | 3984 |
|   |  | Ceftazidime Avibactam : 40 mg/ml<br>Vancomycin hydrochloride : 10 mg/ml      |  | 3984 |
|   |  | Ceftazidime Avibactam : 20 & 40 mg/ml<br>Vancomycin hydrochloride : 5 mg/ml  |  | 3984 |



## Voie d'administration






































## Bibliographie

|      | Type        | Source  |
|------|-------------|---|
| 2902 | Laboratoire | Ceftazidime - avibactam (Avycaz®) - Summary of Product Characteristics<br>Forrest Pharmaceuticals 2015  |
| 3520 | Laboratoire | Cidomycine - Summary of product Characteristics.<br>Sanofi 2011   |
| 3549 | Laboratoire | Amikacine B Braun - Résumé des caractéristiques du produit.<br>B Braun 2012   |
| 3643 | Laboratoire | Gentamicin sulphate (Cidomycine®) - Summary of Product Characteristics<br>Sanofi 2015   |
| 3674 | Laboratoire | Erythromycin lactobionate - Summary of Product Characteristics<br>PanPharma 2016  |
| 3984 | Revue       | Meyer K, Santarossa M, Danziger L.H, Wenzler E.<br>Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in Water.<br>Hosp Pharm 2017 ;52;3 : 221-228 |
| 4055 | Revue       | Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.<br>Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2018 , 75, 1:36-44   |
| 4145 | Revue       | Asempta T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.<br>Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2018 ;75,14:1048-1056           |

|      |       |   |
|------|-------|---|
| 4434 | Revue | Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L.<br>Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.<br>Clin Ther 2019 ; 41, 10: 2162-2170.  |
| 4528 | Revue | Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.<br>Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.<br>Int J Pharm Compound 2021 ;25,1:52-61  |
| 4548 | Revue | O'Donnell J.N, Xu A, Lodise T.P.<br>Intravenous Compatibility of Ceftazidime/Avibactam and Aztreonam Using Simulated and Actual Y-site Administration.<br>Clin Ther 2020 ; 42, 8: 1580-1586.  |
| 4634 | Revue | Loeuille G, D'Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A.<br>Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy.<br>Antibiotics 2022 ;11,4: 458 |
| 4801 | Revue | Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J.<br>Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2024 ;51,1:  |



# Dictionnaire

|   |  |
|---|--|
|  Antibiotique              |  Injectable                     |
|  Noms commerciaux          |  Stabilité des solutions        |
|  Contenant                 |  Molécule                       |
|  Concentration             |  Température                    |
|  Conservation              |  Durée de stabilité             |
|  Biosimilaire              |  Données conflictuelles         |
|  Bibliographie             |  Seringue polypropylène         |
|  NaCl 0,9% ou glucose 5%   |  Lumière                        |
|  Heure                     |  Elastomère en polyisoprène     |
|  Chlorure de sodium 0,9%   |  A l'abri de la lumière         |
|  Non précisé               |  Non précisée                   |
| <b>RL</b> Ringer lactate  |  Compatibilités                 |
|  Molécule                 |  Solvant                       |
|  Instabilité chimique    |  Incompatible                 |
|  Compatible              |  Incompatibilité non précisée |
|  Précipitation immédiate |  Glucose 5%                   |
|  Voie d'administration   |  Perfusion intraveineuse      |
|  Bibliographie           |  Dictionnaire                 |